Inclusion Criteria:  Age ≥ 50 years Informed consent by the subject or legally authorized representative Laboratory-confirmed SARS-CoV-2 infection, as determined by antigen or nucleic acid identification in any specimen, within 4 days of eligibility assessment Peripheral oxygen saturation ≥ 94% on room air and not requiring supplemental oxygen  Onset of symptoms within 4 days of eligibility assessment. Onset time of symptoms is defined as the time when the patient experienced the presence of at least one of the following SARS-CoV-2 infection-associated symptoms for the first time (FDA, September 2020):  Nasal obstruction or congestion Cough Fever >37.3 °C Sore throat Body pain or muscle pain Headache Loss of taste or smell Nausea or vomiting Diarrhoea  Exclusion Criteria:  Previously or currently hospitalized or requiring hospitalization Respiratory distress with respiratory rate ≥ 25 breaths/min Heart rate ≥ 125 beats per minute Peripheral oxygen saturation ≤ 93% on room air at sea level Known allergies to any of the components used in the formulation of the trial drugs Hemodynamic instability requiring use of pressors within 24 hours of randomization Suspected or proven serious, active bacterial, fungal, viral, or other infection (besides COVID-19) that could potentially lead to hospitalization within 30 days Any co-morbidity requiring surgery within 7 days or that is considered life-threatening within 90 days History of positive SARS-CoV-2 serology test History of positive SARS-CoV-2 test prior to 4 days of the eligibility assessment Previous treatment with a SARS-CoV-2 specific monoclonal antibody History of convalescent COVID-19 plasma treatment Participation in a clinical study involving an investigational intervention within the last 30 days Pregnancy or breast feeding Investigator site personnel directly affiliated with this study Sexually active women of childbearing potential or sexually active men who are unwilling to practice effective contraception prior to the initial dose/start of the first treatment, during the study, and for at least 6 months after the last dose Inability to participate to the study follow-up